氨氯地平杂质53 | 67654-56-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 氨氯地平杂质53
• 英文名称: methyl (E)-3-acetamino-2-butenoate
• 英文别名: (E)-3-acetylaminobut-2-enoic acid methyl ester；methyl (E)-β-acetylaminobut-2-enoate；(E)-methyl β-(acetylamino)acrylate；methyl (E)-β-acetylamino butenoate；methyl E-β-N-acetylaminobutenoate；methyl (E)-β-acetamido acrylate；Methyl 3-acetamidobut-2-enoate；methyl (E)-3-acetamidobut-2-enoate
• CAS: 67654-56-2；72569-97-2；136744-85-9
• 化学式: C₇H₁₁NO₃
• 分子量: 157.169
• InChiKey: LZHSHKSQRPIMMV-SNAWJCMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  氨氯地平杂质53 在 palladium on activated charcoal lithium aluminium tetrahydride 、 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 28.5h， 生成 3-乙基氨基-1-丁醇
  参考文献：
  名称：

  Enantioselective synthesis of β-amino acids based on BINAP—ruthenium(II) catalyzed hydrogenation

  摘要：

  BINAP-Ru(II) catalyzed hydrogenation of beta-substituted (E)-beta-(acylamino)acrylic acids allows efficient enantioselective synthesis of beta-amino acids. The Z double bond isomers which possess an intramolecular hydrogen bond between amide and ester groups are more reactive but are hydrogenated with poor enantioselectivity. BINAP-Rh(I) complexes afford only moderate stereoselectivity with the opposite sense of enantioselection.

  DOI：

  10.1016/s0957-4166(00)86107-8
• 作为产物：
  描述：

  3-氨基巴豆酸甲酯 在 吡啶 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 115.0h， 生成 氨氯地平杂质53
  参考文献：
  名称：

  Enantioselective synthesis of β-amino acids based on BINAP—ruthenium(II) catalyzed hydrogenation

  摘要：

  BINAP-Ru(II) catalyzed hydrogenation of beta-substituted (E)-beta-(acylamino)acrylic acids allows efficient enantioselective synthesis of beta-amino acids. The Z double bond isomers which possess an intramolecular hydrogen bond between amide and ester groups are more reactive but are hydrogenated with poor enantioselectivity. BINAP-Rh(I) complexes afford only moderate stereoselectivity with the opposite sense of enantioselection.

  DOI：

  10.1016/s0957-4166(00)86107-8

文献信息

• 2, 3-Bis(dialkylphosphino)pyrazine derivative, process of producing the same, and metal complex having the same as ligand
  申请人：Imamoto Tsuneo

  公开号：US20070021610A1

  公开（公告）日：2007-01-25

  An optically active 2,3-bis(dialkylphosphino)pyrazine derivative represented by formula (1) is disclosed. The pyrazine derivative is preferably a quinoxaline derivative represented by formula (2). In formula (1) and (2), R 1 is preferably a t-butyl or adamantyl group, and R 2 is preferably a methyl group. wherein R 1 is a substituted or unsubstituted, straight chain or branched alkyl group having 2 to 10 carbon atoms; R 2 is a substituted or unsubstituted, straight chain or branched alkyl group having fewer carbon atoms than R 1 ; and R 3 and R 4 , which may be the same or different, are each a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, or R 3 and R 4 are taken together to form a saturated or unsaturated ring. wherein R 1 and R 2 are as defined above; and R 5 is a monovalent substituent.

  公开了一种由式（1）表示的光学活性的2,3-双(二烷基膦基)吡嗪衍生物。该吡嗪衍生物最好是由式（2）表示的喹啉衍生物。在式（1）和（2）中，R1最好是叔丁基或金刚烷基，R2最好是甲基。 其中，R1是取代或未取代的，具有2至10个碳原子的直链或支链烷基基团；R2是取代或未取代的，碳原子比R1少的直链或支链烷基基团；R3和R4，可以相同也可以不同，分别是氢原子或具有1至6个碳原子的烷基基团，或者R3和R4一起形成饱和或不饱和环。 其中，R1和R2如上所定义；R5是一价取代基。
• An Air-Stable P-Chiral Phosphine Ligand for Highly Enantioselective Transition-Metal-Catalyzed Reactions
  作者：Tsuneo Imamoto、Keitaro Sugita、Kazuhiro Yoshida

  DOI：10.1021/ja053458f

  日期：2005.8.1

  A new P-chiral phosphine ligand, (R,R)-2,3-bis(tert-butylmethylphosphino)quinoxaline, has been prepared by the reaction of enantiomerically pure tert-butylmethylphosphine-borane with 2,3-dichloroquinoxaline. This ligand, in contrast to most of the previously reported P-chiral ligands, is an air-stable solid and exhibits excellent enantioselectivities in both Rh-catalyzed asymmetric hydrogenations and

  通过对映异构纯的叔丁基甲基膦硼烷与 2,3-二氯喹喔啉的反应，制备了一种新的 P-手性膦配体，(R,R)-2,3-双（叔丁基甲基膦基）喹喔啉。与大多数先前报道的 P-手性配体相比，该配体是一种空气稳定的固体，在 Rh 催化的不对称氢化和 Rh 或 Pd 催化的碳-碳键形成反应中均表现出优异的对映选择性。
• Cycloolefin phosphine ligands and their use in catalysis
  申请人：Degussa AG

  公开号：EP1595888A1

  公开（公告）日：2005-11-16

  The present invention concerns novel bidentante optionally N-containing P-ligands of general formula (I) embracing a two-ring-system and processes for synthesizing them, transition metal complexes of these compounds and their use as catalysts.

  这项发明涉及一种新颖的双齿可选含氮P配体，其一般公式为（I），包括一个双环系统以及合成它们的过程，这些化合物的过渡金属配合物以及它们作为催化剂的用途。
• Chiral diphosphine ligands based on camphor: synthesis and applications in asymmetric hydrogenations
  作者：Renat Kadyrov、Ilyas Z. Ilaldinov、Juan Almena、Axel Monsees、Thomas H. Riermeier

  DOI：10.1016/j.tetlet.2005.08.103

  日期：2005.10

  The synthesis of a novel class of atropisomer chiral diphosphine ligands with a bornene framework is described. The new ligands showed in Rh catalyzed asymmetric hydrogenation of α- and β-enamides very high ee’s (more than 99%).

  描述了一种新的具有冰片烯骨架的新型阻转异构体手性二膦配体的合成。新的配体在Rh催化的α-和β-酰胺的不对称氢化中显示出很高的ee（超过99％）。
• [EN] NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES AZOTÉS ET LEUR APPLICATION DANS DES MÉDICAMENTS
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2015090232A1

  公开（公告）日：2015-06-25

  The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, IPF, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

  本发明涉及医学领域，提供了新颖的含氮杂环化合物，其制备方法以及作为药物的用途，特别是用于治疗和预防组织纤维化。本文还提供了包含这些含氮杂环化合物的药用可接受组合物，以及这些组合物在治疗人类或动物组织纤维化方面的用途，特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、IPF、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。